BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 37947355)

  • 1. Testicular cancer in 2023: Current status and recent progress.
    McHugh DJ; Gleeson JP; Feldman DR
    CA Cancer J Clin; 2024; 74(2):167-186. PubMed ID: 37947355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response to anti-programmed cell death protein-1 antibodies in men treated for platinum refractory germ cell cancer relapsed after high-dose chemotherapy and stem cell transplantation.
    Zschäbitz S; Lasitschka F; Hadaschik B; Hofheinz RD; Jentsch-Ullrich K; Grüner M; Jäger D; Grüllich C
    Eur J Cancer; 2017 May; 76():1-7. PubMed ID: 28262583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors.
    Nieto Y; Tu SM; Bassett R; Jones RB; Gulbis AM; Tannir N; Kingham A; Ledesma C; Margolin K; Holmberg L; Champlin R; Pagliaro L
    Ann Oncol; 2015 Oct; 26(10):2125-32. PubMed ID: 26199392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Promising novel therapies for relapsed and refractory testicular germ cell tumors.
    Kozakova K; Mego M; Cheng L; Chovanec M
    Expert Rev Anticancer Ther; 2021 Jan; 21(1):53-69. PubMed ID: 33138660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of adolescent males with extracranial metastatic germ cell tumors: A report from the Malignant Germ Cell Tumor International Consortium.
    Shaikh F; Stark D; Fonseca A; Dang H; Xia C; Krailo M; Pashankar F; Rodriguez-Galindo C; Olson TA; Nicholson JC; Murray MJ; Amatruda JF; Billmire D; Stoneham S; Frazier AL
    Cancer; 2021 Jan; 127(2):193-202. PubMed ID: 33079404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current Management of Refractory Germ Cell Tumors.
    Abughanimeh O; Teply BA
    Curr Oncol Rep; 2021 Jul; 23(9):101. PubMed ID: 34269906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Third-line chemotherapy and novel agents for metastatic germ cell tumors.
    Veenstra CM; Vaughn DJ
    Hematol Oncol Clin North Am; 2011 Jun; 25(3):577-91, ix. PubMed ID: 21570610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-Dose Chemotherapy and Autologous Stem Cell Transplant.
    Adra N; Abonour R
    Urol Clin North Am; 2019 Aug; 46(3):439-448. PubMed ID: 31277738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of Salvage High-Dose Chemotherapy in Relapsed Male Germ Cell Tumors.
    Oing C; Lorch A
    Oncol Res Treat; 2018; 41(6):365-369. PubMed ID: 29843143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Testicular germ cell tumors with sarcomatous components: an analysis of 33 cases.
    Guo CC; Punar M; Contreras AL; Tu SM; Pisters L; Tamboli P; Czerniak B
    Am J Surg Pathol; 2009 Aug; 33(8):1173-8. PubMed ID: 19561445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current Management of Disseminated Germ Cell Tumors.
    Lavoie JM; Kollmannsberger CK
    Urol Clin North Am; 2019 Aug; 46(3):377-388. PubMed ID: 31277732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensive and timely chemotherapy, the key of success in testicular cancer.
    Fléchon A; Culine S; Droz JP
    Crit Rev Oncol Hematol; 2001 Jan; 37(1):35-46. PubMed ID: 11164717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medical treatment of advanced testicular cancer.
    Feldman DR; Bosl GJ; Sheinfeld J; Motzer RJ
    JAMA; 2008 Feb; 299(6):672-84. PubMed ID: 18270356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose chemotherapy for male germ cell tumor.
    Hara I; Miyake H; Yamada Y; Takenaka A; Fujisawa M
    Int J Urol; 2006 Aug; 13(8):1037-44. PubMed ID: 16903926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term results of first-line sequential high-dose carboplatin, etoposide and ifosfamide chemotherapy with peripheral blood stem cell support for patients with advanced testicular germ cell tumor.
    Miki T; Mizutani Y; Akaza H; Ozono S; Tsukamoto T; Terachi T; Naito K; Nonomura N; Hara I; Yoshida O;
    Int J Urol; 2007 Jan; 14(1):54-9. PubMed ID: 17199861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical features, presentation, and tolerance of platinum-based chemotherapy in germ cell tumor patients 50 years of age and older.
    Feldman DR; Voss MH; Jacobsen EP; Jia X; Suarez JA; Turkula S; Sheinfeld J; Bosl GJ; Motzer RJ; Patil S
    Cancer; 2013 Jul; 119(14):2574-81. PubMed ID: 23606402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy: last bullet in platinum refractory germ cell testicular cancer.
    Semaan A; Haddad FG; Eid R; Kourie HR; Nemr E
    Future Oncol; 2019 Feb; 15(5):533-541. PubMed ID: 30624089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nivolumab for the salvage treatment of desperate germ cell tumor: A case report.
    Aksun MS; Ucgul E; Sahin TK; Guven DC; Aksoy S
    J Oncol Pharm Pract; 2021 Sep; 27(6):1516-1519. PubMed ID: 33283628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current chemotherapeutic approaches for recurrent or refractory germ cell tumors.
    O'Carrigan B; Grimison P
    Urol Oncol; 2015 Aug; 33(8):343-54. PubMed ID: 25308563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206.
    Adra N; Einhorn LH; Althouse SK; Ammakkanavar NR; Musapatika D; Albany C; Vaughn D; Hanna NH
    Ann Oncol; 2018 Jan; 29(1):209-214. PubMed ID: 29045540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.